RE:RE:RE:Q3 EarningsMy sincere apologies Tim, I just saw Kavern's as always detailed analysis and there was some help from impairment reversals. To be fair though, without those reversals EPS still much better than higher priced competitors. I also agree with Kavern that FFO is the key metric and on that measure we are outperforming pretty much everyone relative to share price.